These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 31518151)

  • 21. Identification of antipsychotic drug fluspirilene as a potential p53-MDM2 inhibitor: a combined computational and experimental study.
    Patil SP; Pacitti MF; Gilroy KS; Ruggiero JC; Griffin JD; Butera JJ; Notarfrancesco JM; Tran S; Stoddart JW
    J Comput Aided Mol Des; 2015 Feb; 29(2):155-63. PubMed ID: 25377899
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Multicomponent Peptide Stapling as a Diversity-Driven Tool for the Development of Inhibitors of Protein-Protein Interactions.
    Ricardo MG; Ali AM; Plewka J; Surmiak E; Labuzek B; Neochoritis CG; Atmaj J; Skalniak L; Zhang R; Holak TA; Groves M; Rivera DG; Dömling A
    Angew Chem Int Ed Engl; 2020 Mar; 59(13):5235-5241. PubMed ID: 31944488
    [TBL] [Abstract][Full Text] [Related]  

  • 23. High specificity in protein recognition by hydrogen-bond-surrogate α-helices: selective inhibition of the p53/MDM2 complex.
    Henchey LK; Porter JR; Ghosh I; Arora PS
    Chembiochem; 2010 Oct; 11(15):2104-7. PubMed ID: 20821791
    [No Abstract]   [Full Text] [Related]  

  • 24. Helical beta-peptide inhibitors of the p53-hDM2 interaction.
    Kritzer JA; Lear JD; Hodsdon ME; Schepartz A
    J Am Chem Soc; 2004 Aug; 126(31):9468-9. PubMed ID: 15291512
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Synthesis of cell-permeable stapled peptide dual inhibitors of the p53-Mdm2/Mdmx interactions via photoinduced cycloaddition.
    Madden MM; Muppidi A; Li Z; Li X; Chen J; Lin Q
    Bioorg Med Chem Lett; 2011 Mar; 21(5):1472-5. PubMed ID: 21277201
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Peptide activators of the p53 tumor suppressor.
    Zhan C; Lu W
    Curr Pharm Des; 2011; 17(6):603-9. PubMed ID: 21391910
    [TBL] [Abstract][Full Text] [Related]  

  • 27. An integrated in silico screening strategy for identifying promising disruptors of p53-MDM2 interaction.
    Sirous H; Chemi G; Campiani G; Brogi S
    Comput Biol Chem; 2019 Dec; 83():107105. PubMed ID: 31473433
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Recent Progress and Clinical Development of Inhibitors that Block MDM4/p53 Protein-Protein Interactions.
    Zhang S; Lou J; Li Y; Zhou F; Yan Z; Lyu X; Zhao Y
    J Med Chem; 2021 Aug; 64(15):10621-10640. PubMed ID: 34286973
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Discovery of novel dual inhibitors against Mdm2 and Mdmx proteins by in silico approaches and binding assay.
    Golestanian S; Sharifi A; Popowicz GM; Azizian H; Foroumadi A; Szwagierczak A; Holak TA; Amanlou M
    Life Sci; 2016 Jan; 145():240-6. PubMed ID: 26746660
    [TBL] [Abstract][Full Text] [Related]  

  • 30. d-Amino acid mutation of PMI as potent dual peptide inhibitors of p53-MDM2/MDMX interactions.
    Li X; Liu C; Chen S; Hu H; Su J; Zou Y
    Bioorg Med Chem Lett; 2017 Oct; 27(20):4678-4681. PubMed ID: 28916339
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Molecular dynamics simulations studies and free energy analysis on inhibitors of MDM2-p53 interaction.
    Niu RJ; Zheng QC; Zhang JL; Zhang HX
    J Mol Graph Model; 2013 Nov; 46():132-9. PubMed ID: 24211465
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Probing Origin of Binding Difference of inhibitors to MDM2 and MDMX by Polarizable Molecular Dynamics Simulation and QM/MM-GBSA Calculation.
    Chen J; Wang J; Zhang Q; Chen K; Zhu W
    Sci Rep; 2015 Nov; 5():17421. PubMed ID: 26616018
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A Unique Mdm2-Binding Mode of the 3-Pyrrolin-2-one- and 2-Furanone-Based Antagonists of the p53-Mdm2 Interaction.
    Surmiak E; Twarda-Clapa A; Zak KM; Musielak B; Tomala MD; Kubica K; Grudnik P; Madej M; Jablonski M; Potempa J; Kalinowska-Tluscik J; Dömling A; Dubin G; Holak TA
    ACS Chem Biol; 2016 Dec; 11(12):3310-3318. PubMed ID: 27709883
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Targeting of p53 peptide analogues to anti-apoptotic Bcl-2 family proteins as revealed by NMR spectroscopy.
    Shin JS; Ha JH; Chi SW
    Biochem Biophys Res Commun; 2014 Jan; 443(3):882-7. PubMed ID: 24342622
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of sequence and stereochemistry reversal on p53 peptide mimicry.
    Atzori A; Baker AE; Chiu M; Bryce RA; Bonnet P
    PLoS One; 2013; 8(7):e68723. PubMed ID: 23922660
    [TBL] [Abstract][Full Text] [Related]  

  • 36. QSAR: hydropathic analysis of inhibitors of the p53-mdm2 interaction.
    Galatin PS; Abraham DJ
    Proteins; 2001 Nov; 45(3):169-75. PubMed ID: 11599019
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Multiple peptide conformations give rise to similar binding affinities: molecular simulations of p53-MDM2.
    Dastidar SG; Lane DP; Verma CS
    J Am Chem Soc; 2008 Oct; 130(41):13514-5. PubMed ID: 18800837
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Autoinhibition of MDMX by intramolecular p53 mimicry.
    Chen L; Borcherds W; Wu S; Becker A; Schonbrunn E; Daughdrill GW; Chen J
    Proc Natl Acad Sci U S A; 2015 Apr; 112(15):4624-9. PubMed ID: 25825738
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Inhibitors of MDM2 and MDMX: a structural perspective.
    Riedinger C; McDonnell JM
    Future Med Chem; 2009 Sep; 1(6):1075-94. PubMed ID: 21425995
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Structural basis for the conserved binding mechanism of MDM2-inhibiting peptides and anti-apoptotic Bcl-2 family proteins.
    Lee MS; Ha JH; Yoon HS; Lee CK; Chi SW
    Biochem Biophys Res Commun; 2014 Feb; 445(1):120-5. PubMed ID: 24491548
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.